Latest Research
All publications from the Cancer3.AI database, newest first.
Integration of Electroporation in Urological Practice: Design and Evaluation of a New Transurethral Electrode.
Laursen RB, et al
Researchers have designed and evaluated a new transurethral electrode intended to bring electroporation-based cancer treatments into standard urological practice for bladder tumors. Electroporation uses short electric pulses to either destroy cancer cells directly (irreversible electroporation) or to enhance drug delivery into cells (reversible electroporation), with calcium electroporation used in this study as a cytotoxic approach. The novel electrode features two opposing arrays of three needles each, with an offset central needle geometry that ensures a uniform, square-shaped electric field, and is designed to fit seamlessly with existing resectoscope equipment used in bladder procedures. Testing was conducted in healthy pig bladders, which closely resemble human bladder anatomy, where calcium was injected into the bladder wall followed by successful delivery of electric pulses through the new electrode. Results demonstrated that the electrode's handling, positioning, and pulse delivery closely mirrored established urological techniques, suggesting that urologists could adopt this tool with minimal additional training. This advancement addresses a significant gap in uro-oncology instrumentation and may open the door to more effective, minimally invasive electroporation-based treatments for bladder cancer patients.
Journal of visualized experiments : JoVE
Source →Nasal morbidity and complications after endoscopic transsphenoidal pituitary adenoma surgery.
Abaza HA, et al
A new study published in Surgical Neurology International examined nasal complications occurring after endoscopic transnasal transsphenoidal (ETT) surgery, the standard minimally invasive technique used to remove pituitary adenomas through the nose. Researchers retrospectively reviewed 414 patients who underwent this procedure at a single institution over a ten-year period from 2015 to 2025, tracking postoperative nasal problems such as nosebleeds, sinus infections, nasal adhesions, smell disturbances, and crusting. Only 17 patients, representing just 4.1% of the cohort, developed any postoperative nasal complication, and all of these resolved with conservative care or minor interventions during follow-up. The most common issues were nasal crusting in six patients and nasal adhesions in four, while more serious problems like epistaxis and olfactory disorders each occurred in only two patients. These findings confirm that ETT surgery carries a low risk of rhinologic morbidity and that complications, when they do occur, are generally manageable and reversible. The results reinforce the safety profile of this surgical approach and highlight the value of attentive postoperative nasal care for patients undergoing pituitary tumor removal.
Surgical neurology international
Source →Coexistence of histologically distinct intracranial tumors: Case series, literature review, and meta-analysis.
Smerdi D, et al
Researchers from a neurosurgical department conducted a retrospective case series and meta-analysis examining patients who simultaneously harbor two histologically distinct intracranial tumors, a phenomenon estimated to occur in fewer than one per million people annually. The study analyzed six patients treated between 2011 and 2025, all presenting with a meningioma alongside a separate intraparenchymal brain tumor, and supplemented this with a systematic literature review encompassing 76 published studies, 16 of which were included in a formal meta-analysis. The most common tumor pairing identified was a meningioma combined with a glioma, while the most frequently reported individual combination across the literature was meningioma with pituitary adenoma, with a pooled mean patient age of 52 years and no significant sex predilection in the broader dataset. Mortality rates were low, and single-stage surgical removal of both tumors emerged as the predominant treatment strategy, with a trend suggesting that older patients were more likely to undergo one-stage surgery. The authors conclude that while surgical intervention remains the gold standard for this rare condition, the underlying biological mechanisms driving the simultaneous development of two unrelated brain tumors remain poorly understood and warrant further investigation.
Surgical neurology international
Source →Topical delivery of Vismodegib using fourth-generation PAMAM dendrimers: a potential treatment for Kaposi's sarcoma.
Ybarra DE, et al
Researchers developed novel nanocarrier systems using fourth-generation PAMAM dendrimers to deliver Vismodegib (VDG), a drug originally approved for skin cancer, directly to the skin as a topical treatment for Kaposi's sarcoma (KS), a vascular tumor often affecting immunocompromised patients. Two dendrimer formulations were created — one bearing hydroxyl groups (G4-OH@VDG) and one functionalized with folic acid (G4-FA@VDG) — both of which dramatically improved the water solubility of VDG and enabled pH-dependent drug release profiles suitable for skin delivery. Laboratory testing confirmed that neither formulation was toxic to healthy skin cells or red blood cells, while both successfully penetrated skin tissue in an ex vivo model, with G4-OH@VDG showing particularly strong accumulation in the outermost skin layer. In an in vitro Kaposi's sarcoma cell model, G4-OH@VDG significantly reduced tumor cell viability and inhibited cell migration at doses below lethal levels, pointing to a favorable therapeutic window. These findings demonstrate that combining drug repurposing strategies with dendrimer nanotechnology offers a promising and safer topical approach to treating Kaposi's sarcoma, potentially reducing the systemic side effects associated with conventional therapies.
International journal of pharmaceutics
Source →Classic Kaposi Sarcoma: Current Treatment Strategies and Emerging Therapeutic Approaches.
Revenko D, et al
A new review published in the journal Cancers examines the current treatment landscape and emerging therapeutic options for Classic Kaposi Sarcoma (CKS), a rare cancer of blood vessel cells caused by the Kaposi sarcoma-associated herpesvirus (KSHV). CKS primarily affects older men and follows a geographically uneven distribution, yet it remains poorly understood compared to other forms of Kaposi sarcoma, such as HIV-related cases. The review highlights that clinical evidence specifically guiding CKS treatment is scarce, with most guidelines and clinical trials focused on HIV-related Kaposi sarcoma, leaving clinicians without strong, evidence-based recommendations for the classic form. Available treatment strategies include local therapies as well as systemic options such as immunotherapy, chemotherapy, and antiangiogenic agents, chosen based on disease stage and patient characteristics. The authors emphasize that while several novel therapies are currently under investigation, significant knowledge gaps persist, and further dedicated research is urgently needed to improve outcomes for CKS patients.
Cancers
Source →